Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940436 | 0.94 | GAA (0.44) | GAAHPGDMAPK1CRBNDDB1 | |
| SCHEMBL6235555 | 0.91 | CRBN (0.43) | GAAHPGDMAPK1CRBNDDB1 | |
| SCHEMBL6239837 | 0.72 | CRBN (0.39) | GAAHPGDCRBNDDB1ALDH1A1 | |
| SCHEMBL6807691 | 0.68 | CRBN (0.40) | GAAHPGDMAPK1CRBNDDB1 | |
| SCHEMBL15229601 | 0.66 | TDP1 (0.42) | GAAHPGDMAPK1TDP1ALDH1A1 | |
| SCHEMBL11284008 | 0.65 | SMN1; SMN2 (0.41) | HPGDMAPK1CRBNDDB1SMN1; SMN2 | |
| SCHEMBL12880750 | 0.64 | TDP1 (0.44) | GAAHPGDMAPK1TDP1ALDH1A1 | |
| SCHEMBL12880751 | 0.64 | TDP1 (0.44) | GAAHPGDMAPK1TDP1ALDH1A1 | |
| SCHEMBL13053338 | 0.63 | ALDH1A1 (0.43) | GAAHPGDMAPK1CRBNDDB1 | |
| SCHEMBL13053343 | 0.63 | ALDH1A1 (0.43) | GAAHPGDMAPK1CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | GAA 163/4885HPGD 241/4885MAPK1 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.